Literature DB >> 12460463

Functional polymorphism of the thymidylate synthase gene in colorectal cancer accompanied by frequent loss of heterozygosity.

Kazuyuki Kawakami1, Yoshinori Ishida, Kathleen D Danenberg, Kenji Omura, Go Watanabe, Peter V Danenberg.   

Abstract

The thymidylate synthase (TS) gene has a polymorphic repeated sequence in its 5'-untranslated region. The repeat length is associated with TS protein expression, which suggests that we may be able to predict the efficacy of 5-fluorouracil (5-FU)-based chemotherapy from a patient's TS genotype determined through analysis of normal tissue obtained non-invasively. However, it is not yet elucidated whether the TS genotype is identical in tumor and normal tissue. In this study, we investigated the TS genotype in 151 matched tumor and normal DNA samples isolated from colorectal cancer and adjacent normal tissues by PCR analysis. The results showed that TS genotypes are identical in normal and tumor tissues of homozygous individuals, suggesting that the repeat sequence is stable through carcinogenesis. However, in heterozygous samples, an imbalance between the 2R and 3R alleles in the tumor DNA was frequently observed, suggesting loss of heterozygosity (LOH) at the TS locus. Detailed LOH analysis revealed that 62% (31 of 50) of 2R/3R-heterozygous samples had LOH. Frequent LOH at the TS locus was confirmed by RT-PCR of TS mRNA and microsatellite analysis using the marker D18S59, located on 18p11.3. There was no difference in the expressions of TS mRNA and TS protein between LOH and non-LOH samples. However, when the heterozygous genotype bearing LOH was subdivided according to the number of repeats, the cancer tissue with 2R/loss genotype expressed a significantly lower level of TS protein than did that with 3R/loss genotype. The results suggest that the difference in TS genotype between tumor and normal tissue due to LOH should be considered when the genotype is analyzed with normal tissue, such as peripheral blood cells, because it is important for TS protein expression.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12460463      PMCID: PMC5926893          DOI: 10.1111/j.1349-7006.2002.tb01227.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN: 0910-5050


  21 in total

1.  Polymorphic tandem repeats in the thymidylate synthase gene is associated with its protein expression in human gastrointestinal cancers.

Authors:  K Kawakami; K Omura; E Kanehira; Y Watanabe
Journal:  Anticancer Res       Date:  1999 Jul-Aug       Impact factor: 2.480

2.  Novel regions of allelic deletion on chromosome 18p in tumors of the lung, brain and breast.

Authors:  Y Tran; K Benbatoul; K Gorse; S Rempel; A Futreal; M Green; I Newsham
Journal:  Oncogene       Date:  1998-12-31       Impact factor: 9.867

3.  Different lengths of a polymorphic repeat sequence in the thymidylate synthase gene affect translational efficiency but not its gene expression.

Authors:  K Kawakami; D Salonga; J M Park; K D Danenberg; H Uetake; J Brabender; K Omura; G Watanabe; P V Danenberg
Journal:  Clin Cancer Res       Date:  2001-12       Impact factor: 12.531

4.  Refinement of regions with allelic loss on chromosome 18p11.2 and 18q12.2 in esophageal squamous cell carcinoma.

Authors:  J D Karkera; S Ayache; R J Ransome; M A Jackson; A F Elsayem; R Sridhar; S D Detera-Wadleigh; R G Wadleigh
Journal:  Clin Cancer Res       Date:  2000-09       Impact factor: 12.531

5.  Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase.

Authors:  D Salonga; K D Danenberg; M Johnson; R Metzger; S Groshen; D D Tsao-Wei; H J Lenz; C G Leichman; L Leichman; R B Diasio; P V Danenberg
Journal:  Clin Cancer Res       Date:  2000-04       Impact factor: 12.531

6.  Polymorphisms of the repeated sequences in the enhancer region of the thymidylate synthase gene promoter may predict downstaging after preoperative chemoradiation in rectal cancer.

Authors:  E Villafranca; Y Okruzhnov; M A Dominguez; J García-Foncillas; I Azinovic; E Martínez; J J Illarramendi; F Arias; R Martínez Monge; E Salgado; S Angeletti; A Brugarolas
Journal:  J Clin Oncol       Date:  2001-03-15       Impact factor: 44.544

7.  CpG island hypermethylation in human colorectal tumors is not associated with DNA methyltransferase overexpression.

Authors:  C A Eads; K D Danenberg; K Kawakami; L B Saltz; P V Danenberg; P W Laird
Journal:  Cancer Res       Date:  1999-05-15       Impact factor: 12.701

8.  Thymidylate synthase expression correlates closely with E2F1 expression in colon cancer.

Authors:  M Kasahara; Y Takahashi; T Nagata; S Asai; T Eguchi; Y Ishii; M Fujii; K Ishikawa
Journal:  Clin Cancer Res       Date:  2000-07       Impact factor: 12.531

9.  Analysis of chromosome 22 deletions in neurofibromatosis type 2-related tumors.

Authors:  R K Wolff; K A Frazer; R K Jackler; M J Lanser; L H Pitts; D R Cox
Journal:  Am J Hum Genet       Date:  1992-09       Impact factor: 11.025

10.  A polymorphism in the enhancer region of the thymidylate synthase promoter influences the survival of colorectal cancer patients treated with 5-fluorouracil.

Authors:  B Iacopetta; F Grieu; D Joseph; H Elsaleh
Journal:  Br J Cancer       Date:  2001-09-14       Impact factor: 7.640

View more
  13 in total

1.  TS gene polymorphisms are not good markers of response to 5-FU therapy in stage III colon cancer patients.

Authors:  A Fariña-Sarasqueta; M J E M Gosens; E Moerland; I van Lijnschoten; V E P P Lemmens; G D Slooter; H J T Rutten; Adriaan J C van den Brule
Journal:  Cell Oncol (Dordr)       Date:  2011-06-01       Impact factor: 6.730

Review 2.  The role of pharmacogenetics in cancer therapeutics.

Authors:  Wei Peng Yong; Federico Innocenti; Mark J Ratain
Journal:  Br J Clin Pharmacol       Date:  2006-07       Impact factor: 4.335

3.  Reexamining a proposal: thymidylate synthase 5'-untranslated region as a regulator of translation efficiency.

Authors:  Soma Ghosh; Jordan M Winter; Kalpesh Patel; Scott E Kern
Journal:  Cancer Biol Ther       Date:  2011-10-15       Impact factor: 4.742

4.  Phase II clinical trial of capecitabine in the treatment of advanced, persistent or recurrent squamous cell carcinoma of the cervix with translational research: a gynecologic oncology group study.

Authors:  Agustin A Garcia; John A Blessing; Kathleen M Darcy; Heinz Josef Lenz; Wu Zhang; Ed Hannigan; David H Moore
Journal:  Gynecol Oncol       Date:  2006-10-17       Impact factor: 5.482

5.  Multifactorial pharmacogenetic analysis in colorectal cancer patients receiving 5-fluorouracil-based therapy together with cetuximab-irinotecan.

Authors:  Marie-Christine Etienne-Grimaldi; Jaafar Bennouna; Jean-Louis Formento; Jean-Yves Douillard; Mireille Francoual; Isabelle Hennebelle; Etienne Chatelut; Eric Francois; Roger Faroux; Chaza El Hannani; Jacques-Henri Jacob; Gérard Milano
Journal:  Br J Clin Pharmacol       Date:  2012-05       Impact factor: 4.335

6.  Loss of the putative tumor suppressor band 4.1B/Dal1 gene is dispensable for normal development and does not predispose to cancer.

Authors:  Chunling Yi; Joseph H McCarty; Scott A Troutman; Matthew S Eckman; Roderick T Bronson; Joseph L Kissil
Journal:  Mol Cell Biol       Date:  2005-11       Impact factor: 4.272

7.  Thymidylate synthase polymorphisms are associated to therapeutic outcome of advanced non-small cell lung cancer patients treated with platinum-based chemotherapy.

Authors:  Aurea Lima; Vítor Seabra; Sandra Martins; Ana Coelho; António Araújo; Rui Medeiros
Journal:  Mol Biol Rep       Date:  2014-02-20       Impact factor: 2.316

8.  Clinical significance of a novel single nucleotide polymorphism in the 5' untranslated region of the Rabphillin-3A-Like gene in colorectal adenocarcinoma.

Authors:  Venkat R Katkoori; Xu Jia; Chakrapani Chatla; Sanjay Kumar; Selvarangan Ponnazhagan; Tom Callens; Ludwine Messiaen; William E Grizzle; Upender Manne
Journal:  Front Biosci       Date:  2008-01-01

9.  Predictive diagnostics in colorectal cancer: impact of genetic polymorphisms on individual outcomes and treatment with fluoropyrimidine-based chemotherapy.

Authors:  Heidi Schwarzenbach
Journal:  EPMA J       Date:  2010-06-04       Impact factor: 6.543

10.  Liver-only metastatic colorectal cancer patients and thymidylate synthase polymorphisms for predicting response to 5-fluorouracil-based chemotherapy.

Authors:  F Graziano; A Ruzzo; F Loupakis; D Santini; V Catalano; E Canestrari; P Maltese; R Bisonni; L Fornaro; G Baldi; G Masi; A Falcone; G Tonini; P Giordani; P Alessandroni; L Giustini; B Vincenzi; M Magnani
Journal:  Br J Cancer       Date:  2008-08-12       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.